<DOC>
	<DOCNO>NCT00434252</DOCNO>
	<brief_summary>This Phase II , multicenter , randomize , double-blind , placebo-controlled trial design estimate efficacy characterize safety bevacizumab combine carboplatin + paclitaxel chemotherapy compare carboplatin + paclitaxel chemotherapy alone patient previously untreated metastatic melanoma .</brief_summary>
	<brief_title>A Study Bevacizumab With Carboplatin Paclitaxel Chemotherapy First-Line Treatment Patients With Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Signed Informed Consent Form Age â‰¥ 18 year Metastatic melanoma ( Stage IV ) Histologically confirm malignant melanoma measurable nonmeasurable disease Ability willingness comply study followup procedure Prior treatment Stage IV disease chemotherapy biologic therapy interferon interleukin2 Complete surgical resection irradiation identifiable site disease randomization Radiation therapy within 14 day prior Day 1 Prior therapy bevacizumab , sorafenib , sunitinib , vascular endothelial growth factor ( VEGF ) pathwaytargeted therapy Melanoma ocular origin Known central nervous system ( CNS ) disease/brain metastasis ( history brain disease active disease ) Life expectancy &lt; 12 week Current , recent , planned participation experimental drug study Genentechsponsored bevacizumab cancer study Inadequate organ function History malignancy within 5 year Day 1 , except tumor negligible risk metastasis death , adequately control basal cell carcinoma squamouscell carcinoma skin carcinoma situ cervix Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render patient high risk treatment complication Inadequately control hypertension History hypertensive crisis hypertensive encephalopathy New York Heart Association ( NYHA ) Class II great CHF History myocardial infarction unstable angina within 6 month prior Day 1 History stroke transient ischemic attack within 6 month prior Day 1 Significant vascular disease ( e.g. , aortic aneurysm , aortic dissection ) recent peripheral arterial thrombosis within 6 month prior Day 1 History hemoptysis within 1 month prior Day 1 Evidence bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 1 anticipation need major surgical procedure course study Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior Day 1 History abdominal fistula gastrointestinal perforation within 6 month prior Day 1 Serious , nonhealing wound , active ulcer , untreated bone fracture Known hypersensitivity component bevacizumab Pregnancy ( positive pregnancy test ) lactation Current , ongoing treatment fulldose warfarin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Avastin</keyword>
	<keyword>BEAM</keyword>
	<keyword>Metastatic melanoma</keyword>
</DOC>